Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)

Following a request from the company, the timelines for this appraisal have been revised. The committee meeting will be held on 12 March 2025.